About SPRAVATO®
How It Works.
There is another Option
Depression can be overwhelming, debilitating and at times hopeless. For Treatment-Resistant Depression Spravato can be your best option.
Imagine the smile
Intranasal esketamine is the first medication approved by the FDA for difficult to treat depressive episode that meet criteria for TRD. Approved in the United States in 2019,
Take The Next Step
FDA Indications for Spravato
There are two FDA-approved indications for esketamine. According to the esketamine package insert, “SPRAVATO®esketamine) is indicated, in conjunction with an oral antidepressant, for the treatment of treatment-resistant depression (TRD) in adults and depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation (SI) or behavior”
Treatment Protocol
The treatment recommended for Treatment Resistant Depression is twice per week for four weeks followed by weekly by four weeks. Patients are monitored and supervised during treatment for 2 hours and must remain in the treatment facility. Patients must have a documented safe ride home. Patients cannot drive until a full night's rest.
Helpful Tips
1. No liquids 30 minutes prior to administration
2. No food for 2 hours prior to administration
3. No nasal decongestant spray / steroid
4. No operation of machinery or vehicle until patient had a good nights rest, may need to be with some one upon discharge
Contact Us
If you have any questions or concerns, don't hesitate to contact us. Our friendly staff are always here to help. You can reach us via phone, email, or by filling out our online contact form.